Search

Armata Pharmaceuticals announced a $20 Million investment to support advancement of its clinical phage development programs. Armata aims to complete a phage clinical trial (Phase 1b/2a, P. aeruginosa) and initiate three more in 2021-2022.

US biotech company Felix Biotechnology announced the initiation of its first clinical trial, CYPHY, a phase 1/2 single center trial that will test its first targeted phage therapy candidate, YPT-01, against chronic P. aeruginosa infections

BiomX has announced the dosing of their first subject in their Phase 1a clinical study testing the safety, pharmacokinetics and oral delivery of a phage therapy candidate for treatment of Inflammatory Bowel Disease. Results are expected in

The FDA has authorized Armata Pharmaceuticals to initiate a phase 1b/2a clinical trial, which they are calling "SWARM-P.a.", to test AP-PA02, its lead phage cocktail candidate, against Pseudomonas aeruginosa airway infections in cystic fibr

Micreos has initiated a clinical trial to evaluate a topically-applied phage endolysin as a therapy for Atopic Dermatitis.

PhagePro is looking for a Scientist I to participate in our research on our cholera phage cocktail as we prepare for clinical trials. The position is located at PhagePro’s lab space at the Tufts Launchpad in Boston, MA. Please visit our web

Lorenz Leitner (Balgrist University Hospital, Switzerland) and colleagues published a new paper in The Lancet Infectious Diseases on the results of a randomised, placebo-controlled, double-blind clinical trial to investigate intravesical ph

PhagePro is looking for a Scientist II to participate in our research on our cholera phage cocktail as we prepare for clinical trials. The position is located at PhagePro’s lab space at the Tufts Launchpad in Boston, MA. Please visit our we

Diana Grubb (Colorado State University) and colleagues tested a phage prebiotic produced by Deerland Enzymes (Kennesaw, Georgia) in a placebo-controlled human clinical study, and found that administration of a phage cocktail alongside a bac

The Mayo Clinic has invested $1.75 million in Adaptive Phage Therapeutics, which will allow APT to initiate a clinical trial to address periprosthetic joint infections (an estimated commercial market of $900 million per year). The trial is

Christopher Duplessis and Biswajit Biswas (US Naval Medical Research Center) published a new systematic review in Antibiotics on topical phage therapy for chronically infected wounds. They also discuss their preparations for a phase II rand

Intralytix is recruiting patients for its Crohn's disease clinical trial out of Mount Sinai Hospital in New York. They will be evaluating patient stool samples for presence of adherent invasive E. coli (AIEC), and if positive, patients will

Armata Pharmaceuticals just received a $15 million award from the US Department of Defense to take its Staphylococcus aureus phage cocktail to phase 1b/2 clinical trials.

Intralytix is a phage company in Maryland, USA that began in 1998 developing phage products for food; recently they've moved toward human therapy. Read about their recent progress here, including their new NIAID-funded Shigella phage clinic

US biotech company Intralytix was just awarded a multimillion dollar grant from NIAID to perform a phase 1/2a clinicial trial to assess safety and efficacy of phage therapy against Shigella.

US biotech company Intralytix was just awarded a multimillion dollar grant from NIAID to perform a phase 1/2a clinicial trial to assess safety and efficacy of phage therapy against Shigella.